Celgene to buy Juno Therapeutics for $9 billion | | (Reuters) - Celgene Corp said on Monday it would pay about $9 billion in cash to acquire the rest of Juno Therapeutics Inc and gain access to Juno's experimental gene therapy to treat cancer. |
| |
| | | | | | Related Video |
| | | | | | | | Related News |
| | | | | | | | | | Make sense of the market with highlights of valuable financial information and reports along with compelling investment insights. Register Today | |
| | | | Get a jump on the day with our early morning summary of key news developments for the US markets, as well as global market news. Register Today | |
| | » » MORE NEWSLETTERS | |
|